Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer (HBOT)
Primary Purpose
Impotence, Prostatic Neoplasms
Status
Unknown status
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Sildenafil therapy plus post-NSRRP HBO2T
Sildenafil therapy plus sham post-NSRRP HBO2T
Sponsored by
About this trial
This is an interventional treatment trial for Impotence focused on measuring impotence, prostatic neoplasms, hyperbaric oxygenation, Phosphodiesterase Inhibitors
Eligibility Criteria
Inclusion Criteria:
- male
- age 40-69
- diagnosis of Stage I prostate cancer
- bilateral NSRRP as primary treatment
- sexual potency prior to surgery
Exclusion Criteria:
- COPD, CHF, diabetes mellitus
- known inability to tolerate PDE5I
- confinement anxiety/claustrophobia
- planned adjuvant or neo-adjuvant therapy
- patients taking alpha blockers or nitrates
- patients with retinitis pigmentosa
Sites / Locations
- Hartford Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
Erectile function domain of Internation Index of Erectile Function (IIEF)
Secondary Outcome Measures
clinical or biochemical recurrence of cancer
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00906269
Brief Title
Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
Acronym
HBOT
Official Title
Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
May 2019
Overall Recruitment Status
Unknown status
Study Start Date
July 2009 (undefined)
Primary Completion Date
July 2020 (Anticipated)
Study Completion Date
January 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hartford Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine if adding hyperbaric oxygen therapy, a therapy that delivers oxygen under slight pressure, to a drug treatment of PDE5I (such as Viagra, Levitra, Cialis)for men following surgery for prostate cancer will result in more men being able to continue to have erections.
Detailed Description
Prostate cancer is the most common non-skin malignancy in men in the United States, with approximately 232,000 diagnoses of adenocarcinoma projected for 2005. More than 150,000 of these men are treated with radical prostatectomy. Common sequelae following successful NSRRP (nerve-sparing radical retropubic prostatectomy)include urinary incontinence and sexual dysfunction. Recent advances in surgery technique and treatment have been made but in spite of aggressive management, recovery of sexual function is incomplete with fewer than one-fifth reporting return to baseline. The etiology of erectile dysfunction following radical prostatectomy results most probably from local surgical trauma and neurapraxia, which leads to corpus cavernosal hypoxemia in the post-NSRRP period. This hypoxemia is believed to impact negatively on the health and maintenance of the smooth muscle cells within the corpus cavernosum. Hyperbaric oxygen therapy (HBO2T) is a unique modality that is able to provide oxygen delivery to tissues that have been damaged by traumatic injury.
Hypothesis: The addition of post-NSRRP hyperbaric oxygen therapy (HBO2T) to a treatment of phosphodiesterase type 5 inhibitor (PDE5I) will reduce the incidence of erectile dysfunction (ED) and urinary incontinence when measured at 1, 3, 6, 12 and 18 months post-NSRRP for Stage I prostate cancer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Impotence, Prostatic Neoplasms
Keywords
impotence, prostatic neoplasms, hyperbaric oxygenation, Phosphodiesterase Inhibitors
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Sham Comparator
Intervention Type
Drug
Intervention Name(s)
Sildenafil therapy plus post-NSRRP HBO2T
Other Intervention Name(s)
Viagra
Intervention Description
Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
Intervention Type
Drug
Intervention Name(s)
Sildenafil therapy plus sham post-NSRRP HBO2T
Other Intervention Name(s)
Viagra
Intervention Description
Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
Primary Outcome Measure Information:
Title
Erectile function domain of Internation Index of Erectile Function (IIEF)
Time Frame
1, 3, 6, 12, and 18 months post surgery
Secondary Outcome Measure Information:
Title
clinical or biochemical recurrence of cancer
Time Frame
up to 10 years
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
male
age 40-69
diagnosis of Stage I prostate cancer
bilateral NSRRP as primary treatment
sexual potency prior to surgery
Exclusion Criteria:
COPD, CHF, diabetes mellitus
known inability to tolerate PDE5I
confinement anxiety/claustrophobia
planned adjuvant or neo-adjuvant therapy
patients taking alpha blockers or nitrates
patients with retinitis pigmentosa
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Graydon, MD
Organizational Affiliation
Hartford Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hartford Hospital
City
Hartford
State/Province
Connecticut
ZIP/Postal Code
06106
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
15928287
Citation
Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005 Jun 1;293(21):2648-53. doi: 10.1001/jama.293.21.2648.
Results Reference
background
PubMed Identifier
8858398
Citation
Mulhall JP, Graydon RJ. The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Int J Impot Res. 1996 Jun;8(2):91-4.
Results Reference
background
PubMed Identifier
7120554
Citation
Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982 Sep;128(3):492-7. doi: 10.1016/s0022-5347(17)53012-8. No abstract available.
Results Reference
background
PubMed Identifier
9187685
Citation
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-30. doi: 10.1016/s0090-4295(97)00238-0.
Results Reference
background
PubMed Identifier
11113727
Citation
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000 Dec 20;56(6):899-905. doi: 10.1016/s0090-4295(00)00858-x.
Results Reference
background
Citation
Feldmeier, J.J.,Chairman and Editor. Hyperbaric Oxygen 2003: Indications and Results. The Hyperbaric Oxygen Therapy Committee Report . Kensington, MD: Undersea and Hyperbaric Medicine Society, 2003.
Results Reference
background
Citation
Feldmeier JJ. Hyperbaric oxygen: does it have a cancer causing or growth enhancing effect? In: Proceeding of the Concensus Conference sponsored by the European Society for Therapeutic Radiology and Oncology and the European Committee for Hyperbaric Medicine. Portugal 2001: 129-146
Results Reference
background
PubMed Identifier
15592069
Citation
Link RE, Su LM, Sullivan W, Bhayani SB, Pavlovich CP. Health related quality of life before and after laparoscopic radical prostatectomy. J Urol. 2005 Jan;173(1):175-9; discussion 179. doi: 10.1097/01.ju.0000147190.67218.1b.
Results Reference
result
PubMed Identifier
7714876
Citation
Zamboni WA, Brown RE, Roth AC, Mathur A, Stephenson LL. Functional evaluation of peripheral-nerve repair and the effect of hyperbaric oxygen. J Reconstr Microsurg. 1995 Jan;11(1):27-9; discussion 29-30. doi: 10.1055/s-2007-1006507.
Results Reference
result
PubMed Identifier
15310998
Citation
Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004 Sep;172(3):920-2. doi: 10.1097/01.ju.0000136269.10161.32.
Results Reference
result
PubMed Identifier
10524880
Citation
Lowentritt BH, Scardino PT, Miles BJ, Orejuela FJ, Schatte EC, Slawin KM, Elliott SP, Kim ED. Sildenafil citrate after radical retropubic prostatectomy. J Urol. 1999 Nov;162(5):1614-7.
Results Reference
result
PubMed Identifier
14713808
Citation
Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol. 2004 Feb;171(2 Pt 1):771-4. doi: 10.1097/01.ju.0000106970.97082.61.
Results Reference
result
Links:
URL
http://www.harthosp.org
Description
Hartford Hospital Home Page
Learn more about this trial
Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
We'll reach out to this number within 24 hrs